The Role of HER2 Status in the Biliary Tract Cancers

Simple Summary Human epidermal growth factor receptor-2 (HER2) plays a critical role in breast and gastric cancer. More recently, a growing body of literature demonstrated that HER2 is involved in biliary tract cancers. In this review, we discuss the potential therapeutic utilization of HER2-blocking antibodies and ongoing clinical trials assessing the efficacy of HER2-blocking antibodies in HER2-altered and/or -amplified biliary tract cancers. Abstract Despite recent advances, biliary tract cancer (BTC) is traditionally known as being hard to treat with a poor prognosis. Recent state-of-the-art genomic technologies such as next-generation sequencing (NGS) revolutionized cancer management and shed light on the genomic landscape of BTCs. There are ongoing clinical trials to assess the efficacy of HER2-blocking antibodies or drug conjugates in BTCs with HER2 amplifications. However, HER2 amplifications may not be the sole eligibility factor for these clinical trials. In this review, we aimed to comprehensively examine the role of somatic HER2 alterations and amplifications in patient stratification and provide an overview of the current state of ongoing clinical trials.

[1]  I. Sahin,et al.  Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer. , 2023, The lancet. Gastroenterology & hepatology.

[2]  R. Epstein,et al.  Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. , 2023, The New England journal of medicine.

[3]  I. Nagtegaal,et al.  Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients , 2022, npj Precision Oncology.

[4]  J. Mayordomo,et al.  Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. , 2022, The Lancet. Oncology.

[5]  Min Hwan Kim,et al.  Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). , 2022, The lancet. Gastroenterology & hepatology.

[6]  Hongjian Yang,et al.  Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies , 2022, Frontiers in Pharmacology.

[7]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[8]  M. Berger,et al.  Targeting HER2 mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial. , 2022, Journal of Clinical Oncology.

[9]  Jiahong Dong,et al.  Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance , 2022, Frontiers in Oncology.

[10]  Xiaoqing Cai,et al.  Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers , 2022, Frontiers in Molecular Biosciences.

[11]  Joon-Oh Park,et al.  HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer , 2022, Frontiers in Oncology.

[12]  R. Shroff,et al.  Current and emerging therapies for advanced biliary tract cancers. , 2021, The lancet. Gastroenterology & hepatology.

[13]  S. Choe,et al.  Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation , 2021, JAMA oncology.

[14]  P. Jänne,et al.  Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. , 2021, The New England journal of medicine.

[15]  P. Philip,et al.  Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. , 2021, The lancet. Gastroenterology & hepatology.

[16]  J. Hainsworth,et al.  Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. , 2021, The Lancet. Oncology.

[17]  M. Gold,et al.  Abstract 1005: The bispecific antibody zanidatamab's (ZW25's) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers , 2021, Experimental and Molecular Therapeutics.

[18]  Y. Ba,et al.  Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors , 2021, Gastric Cancer.

[19]  W. Ryder,et al.  Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial , 2021, The Lancet. Oncology.

[20]  G. Brandi,et al.  Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. , 2021, Cancer treatment and research communications.

[21]  I. Ben-Aharon,et al.  ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway , 2020, Oncology Research and Treatment.

[22]  R. F. van Golen,et al.  Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer. , 2020, The Lancet. Oncology.

[23]  N. Hiraoka,et al.  Details of HER2 status in 454 cases of biliary tract cancer. , 2020, Human pathology.

[24]  R. Greil,et al.  Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. , 2020, The Lancet. Oncology.

[25]  Mark Robson,et al.  Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  A. Mahipal,et al.  Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm , 2020, Cancers.

[27]  F. Meric-Bernstam,et al.  Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  E. Vasile,et al.  HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer. , 2020, The oncologist.

[29]  E. Van Cutsem,et al.  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. , 2020, The Lancet. Oncology.

[30]  Y. Bang,et al.  HER2-targeted therapies — a role beyond breast cancer , 2019, Nature Reviews Clinical Oncology.

[31]  G. Mariani,et al.  Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. , 2019, Critical reviews in oncology/hematology.

[32]  S. Taylor-Robinson,et al.  Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis. , 2019, Journal of hepatology.

[33]  Funda Meric-Bernstam,et al.  Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer , 2018, Clinical Cancer Research.

[34]  S. Durinck,et al.  Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. , 2018, Cancer cell.

[35]  James M. Bogenberger,et al.  Emerging role of precision medicine in biliary tract cancers , 2018, npj Precision Oncology.

[36]  A. Zhu,et al.  New Horizons for Precision Medicine in Biliary Tract Cancers. , 2017, Cancer discovery.

[37]  M. Ellis,et al.  Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer , 2017, Clinical Cancer Research.

[38]  Marie-Cécile Le Deley,et al.  High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.

[39]  C. Sotiriou,et al.  HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 , 2017, Clinical Cancer Research.

[40]  C. Cella,et al.  Non-thematic Review , 2022 .

[41]  Y. Bang,et al.  Therapeutic implication of HER2 in advanced biliary tract cancer , 2016, Oncotarget.

[42]  A. Ata,et al.  Prognostıc Value of Increased her2 Expression in Cancers of Pancreas and Biliary Tree , 2015, Pathology & Oncology Research.

[43]  Li Ding,et al.  Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.

[44]  M. Vijver,et al.  HER2 testing in gastric cancer: a practical approach , 2012, Modern Pathology.

[45]  T. Bekaii-Saab,et al.  HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib , 2012, Oncology.

[46]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[47]  A. Bardelli,et al.  Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas , 2010, BMC Cancer.

[48]  Yun Yen,et al.  A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer , 2009, Cancer Chemotherapy and Pharmacology.